Early renal recovery after acute kidney injury in patients on venoarterial extracorporeal membrane oxygenation: A retrospective study.
Acute kidney injury
Cardiogenic shock
Fluid balance
Renal recovery
Veno-arterial extracorporeal membrane oxygenation
Journal
Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
05
04
2023
revised:
21
06
2023
accepted:
03
07
2023
medline:
25
9
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
The impact of VA-ECMO on early renal recovery (within 7 days after ECMO onset) in patients with pre-ECMO acute kidney injury and cardiogenic shock is unknown. This retrospective single-center study included adult patients with cardiogenic shock rescued by VA-ECMO and severe AKI occurring before ECMO implantation (pre-ECMO AKI). Patients with early renal recovery (defined as at least a 50% decrease in peak serum creatinine or weaning from renal replacement therapy) were compared to patients without early renal recovery. During 7 years, 145 patients with severe pre-ECMO AKI were included. Eighty-two patients had no early renal recovery whereas 63 had early renal recovery within 7 days after VA-ECMO onset. The median time to early renal recovery was 4 (3,6) days. Nephrotoxic antibiotics (HR = 0.35 [95% CI, 0.21-0.59], p < 0.001), median fluid balance during the first 7 days of VA-ECMO (HR = 0.77 [95% CI, 0.64-0.93], p = 0.008), pre-ECMO AKI stage 3 (HR = 0.36 [95% CI, 0.20-0.64], p < 0.001) and median vasoactive-inotropic score (HR = 0.99 [95% CI, 0.98,1.00], p = 0.035) were independently associated with no early renal recovery. Only 43% of patients with severe pre-ECMO AKI had early renal recovery after VA-ECMO initiation.
Identifiants
pubmed: 37540960
pii: S0883-9441(23)00117-X
doi: 10.1016/j.jcrc.2023.154368
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154368Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Pr Combes reports grants from Getinge, and personal fees from Getinge, Baxter, and Xenios outside the submitted work. Pr Schmidt reports receiving personal fees from Getinge, Baxter, and Xenios, outside the submitted work. No other disclosures were reported.